FDA’s rating of Syntex' Synarel
When Synarel (transnasal nafarelin) was approved in February for treating endometriosis, FDA gave the drug a "1B" rating denoting a new chemical entity representing a modest therapeutic gain over existing therapies ("The Pink Sheet" Feb. 19, p. 3). However, as indicated in FDA's list of February approvals, the agency changed Synarel's rating to "1 C" or a new chemical entity offering little or no therapeutic gain ("The Pink Sheet" April 16, p. 11). According to FDA, the agency decided to change the rating because it was determined that Synarel has a side effect profile similar to an already approved endometriosis treatment, Sterling's danazol (Danocrine). FDA had originally thought that Synarel's side effect profile was better than danazol's.
You may also be interested in...
The independent, family-controlled German group has signed a third R&D pact with Danish biotech Gubra to develop poly-agonist peptides for obesity.
Inovio Pharmaceuticals has reported promising initial data from its first Phase III study of its electrical current-driven DNA plasmid-based immunotherapy, VGX-3100, in virus-associated cervical dysplasia; it is heading a small group of companies evaluating novel therapies in the condition, which often advances to cancer.
In the month ahead, a key ANDA approval could come for Viatris, while additional competition to Gilead Sciences’ Truvada for PrEP is on the way in the US following Teva and Amneal’s launches.